Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziresovir in hospitalized adult RSV patients
NCT06942299Phase 2Completed
- Sponsor
- Ark Biosciences
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Started Jul 2023; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06942299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06942299.